HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (37) Citing Articles via Google Scholar Google Scholar Articles by Stenman, U.-H. Search for Related Content PubMed PubMed Citation Articles by Stenman, U.-H. Related Collections Laboratory Management Clinical Immunology Proteomics and Protein Markers Lipids, Lipoproteins, and Cardiovascular Risk Factors Drug Monitoring and Toxicology Endocrinology and Metabolism

Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?

¹ Department of Clinical Chemistry, Helsinki University Central Hospital, POB 140, FIN-00029 Helsinki, Finland

^aAuthor for correspondence. Fax 358-9-47174804; E-mail ulf-hakan.stenman@hus.fi.

	Introduction

 
Standardization in clinical chemistry aims at improving trueness, i.e., lack of bias, but it does not directly affect assay imprecision. Standardization is important because it facilitates clinical interpretation and comparison of results from various studies (1)(2). This is especially important with analytes used for screening, and this was one reason that cholesterol assays have been standardized in the US (3). Standardization of assays for prostate-specific antigen (PSA) is important for the same reason, and also because these assays are important for monitoring of disease progression in prostate cancer. Large differences in assay calibration lead to misinterpretations of the clinical course when different assays are used (4). Variation in assays for chorionic gonadotropin (CG) (5) cause similar problems when women with pregnancy-related disorders are monitored by determination of CG in serum (6). It is a testimony of the clinical importance of standardization that the preparation of standards for PSA was initiated and carried out by a urologist, Thomas Stamey from Stanford (7).

Standardization is a fairly new concept in clinical chemistry. The notion of "comprehensive measurement systems" and various levels of reference methods evolved in the 1970s (1)(2) and was formulated by Tietz in 1979 (8). Pure standards, reference methods, and standard reference materials (SRMs) are now available for many of the most important analytes determined by conventional chemical methods, but immunoassay standardization is less well developed. Immunoassay standardization was extensively discussed at two meetings organized in 1990 and 1992 by the IFCC. At these, two standardization projects were initiated: the one for cortisol was intended to serve as a model for hapten immunoassays, the other project, for standardization of assays for CG, was intended to serve as a pilot study . . . [Full Text of this Article]

	Is Immunoassay Standardization Possible?

 
primary standards and assignment of values for these
assay design
epitope mapping
reference methods
serum-based reference materials
using commercial assays as reference methods

	Who Is Responsible?

 

	Who Is Capable?

 

	Alternative Approaches

 
leave the problem to the industry
harmonization
method-specific reference values
risk calculation
external quality assessment

	Conclusions

 

	References

 

The following articles in journals at HighWire Press have cited this article:

				R. Sapin Insulin Immunoassays: Fast Approaching 50 Years of Existence and Still Calling for Standardization Clin. Chem., May 1, 2007; 53(5): 810 - 812. [Full Text] [PDF]

				S. E. Manley, I. M. Stratton, P. M. Clark, and S. D. Luzio Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation and Research Clin. Chem., May 1, 2007; 53(5): 922 - 932. [Abstract] [Full Text] [PDF]

				N. Ljungdahl, M. Haarhaus, C. Linder, and P. Magnusson Comparison of 3 Third-Generation Assays for Bio-intact Parathyroid Hormone. Clin. Chem., May 1, 2006; 52(5): 903 - 904. [Full Text] [PDF]

				L. M. Thienpont, K. Van Uytfanghe, J. Marriott, P. Stokes, L. Siekmann, A. Kessler, D. Bunk, and S. Tai Feasibility Study of the Use of Frozen Human Sera in Split-Sample Comparison of Immunoassays with Candidate Reference Measurement Procedures for Total Thyroxine and Total Triiodothyronine Measurements Clin. Chem., December 1, 2005; 51(12): 2303 - 2311. [Abstract] [Full Text] [PDF]

				M. Panteghini Standardization of Cardiac Troponin I Measurements: The Way Forward? Clin. Chem., September 1, 2005; 51(9): 1594 - 1597. [Full Text] [PDF]

				U.-H. Stenman Improving Immunoassay Performance by Antibody Engineering Clin. Chem., May 1, 2005; 51(5): 801 - 802. [Full Text] [PDF]

				D. H. Wilson, G. Williams, R. Herrmann, D. Wiesner, and P. Brookhart Issues in Immunoassay Standardization: The ARCHITECT Folate Model for Intermethod Harmonization Clin. Chem., April 1, 2005; 51(4): 684 - 687. [Full Text] [PDF]

				M. L. Rawlins and W. L. Roberts Performance Characteristics of Six Third-Generation Assays for Thyroid-Stimulating Hormone Clin. Chem., December 1, 2004; 50(12): 2338 - 2344. [Abstract] [Full Text] [PDF]

				M. Panteghini and F. Pagani AACC Creatine Kinase MB (CK-MB) Standardization Material Used as Manufacturer's Working Calibrator Is Unable to Harmonize CK-MB Results between Two Commercial Immunoassays Clin. Chem., September 1, 2004; 50(9): 1711 - 1712. [Full Text] [PDF]

				N. Binkley, D. Krueger, C. S. Cowgill, L. Plum, E. Lake, K. E. Hansen, H. F. DeLuca, and M. K. Drezner Assay Variation Confounds the Diagnosis of Hypovitaminosis D: A Call for Standardization J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3152 - 3157. [Abstract] [Full Text] [PDF]

				U.-H. Stenman Standardization of Assays for Human Chorionic Gonadotropin Clin. Chem., May 1, 2004; 50(5): 798 - 800. [Full Text] [PDF]

				S. Wesseling, C. Stephan, A. Semjonow, M. Lein, B. Brux, P. Sinha, S. A. Loening, and K. Jung Determination of Non-{alpha}1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy Clin. Chem., June 1, 2003; 49(6): 887 - 894. [Abstract] [Full Text] [PDF]

				U.-H. Stenman Standardization as a Private Enterprise Clin. Chem., April 1, 2003; 49(4): 535 - 536. [Full Text] [PDF]

				P. Glendenning Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D Am. J. Clinical Nutrition, February 1, 2003; 77(2): 522 - 523. [Full Text] [PDF]

				M. Panteghini Performance of Today's Cardiac Troponin Assays and Tomorrow's Clin. Chem., June 1, 2002; 48(6): 809 - 810. [Full Text] [PDF]

				R. M. Lequin and U.-H. Stenman Standardization: Comparability and Traceability of Laboratory Results Dr. Stenman responds: Clin. Chem., February 1, 2002; 48(2): 391 - 393. [Full Text] [PDF]